INCHEON, Korea, Nov 23 (Bernama-BUSINESS WIRE) -- Samsung
Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA)
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive
opinion on Benepali® – a biosimilar version of Enbrel® (etanercept),
previously known as SB4 – for the treatment of rheumatoid arthritis, psoriatic
arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic
axial spondyloarthritis) and plaque psoriasis. This marks the first time the
CHMP has adopted a positive opinion on an etanercept biosimilar.
No comments:
Post a Comment